A Subacute Cutaneous Lupus Erythematosus-Like Drug Eruption Related to Terbinafine in a Male
Main Article Content
Keywords
Subacute cutaneous lupus erythematosus, terbinafine, drug eruption
Abstract
Patients with a history of or a predisposition to autoimmune or collagen vascular diseases are inclined to develop drug-induced subacute cutaneous lupus erythematosus (SCLE) due to terbinafine therapy. Here, we report a case of terbinafine-induced SCLE in a male patient, although classic SCLE most commonly affects females, and he did not have a diagnosis of or a history suggestive of a predisposition to autoimmune or collagen vascular diseases. Although the mechanism for terbinafine-induced SCLE has not been fully elucidated, we suggest that there may be distinctive mechanisms of terbinafine-induced SCLE of patients with and without a predisposition to or history of autoimmune or connective tissue diseases, which should be a focus of future research.
References
2. Hivnor CM, Hudkins ML, Bonner B. Terbinafine-Induced subacute cutaneous lupus erythematosus. Cutis 2008;81(2):156-157.
3. McKay DA, Schofield OM, Benton EC. Terbinafine-induced subacute cutaneous lupus erythematosus. Acta Derm Venereol 2004;84(6):472-474.
4. Cetkovská P, Pizinger K. Coexisting subacute and systemic lupus erythematosus after terbinafine administration: successful treatment with mycophenolate mofetil. Int J Dermatol 2006;45(3):320-322.
5. Tappel AC, Tiwari N, Saavedra A. Terbinafine-induced relapse of bullous lupus erythematosus. J Clin Rheumatol 2018.
6. Kalińska-Bienias A, Kowalewski C, Woźniak K. Terbinafine-induced subacute cutaneous lupus erythematosus in two patients with systemic lupus erythematosus successfully treated with topical corticosteroids. Postepy Dermatol Alergo 2013;30(4):261-264.
7. Kasperkiewicz M, Anemüller W, Angelova-Fischer I, Rose C, Zillikens D, Fischer TW. Subacute cutaneous lupus erythematosus associated with terbinafine. Clin Exp Dermatol 2009;34(7):e403-e404.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.